Plasmakinin

Plasmakinin, also known as coagulation factor XI, is a glycoprotein that plays an important role in the blood coagulation system. Plasmakinin was discovered in 1952 by American scientists Edward Frankland and Rosemary Biggs.

In the blood, plasmakinin is in an inactive form and is activated only in the presence of certain factors, such as factor XII, collagen and some other damaged tissues. Activated plasmakinin in turn activates factor IX, which leads to the formation of thrombin and subsequent blood clotting.

In addition to its role in the blood coagulation system, plasmakinin can also influence the immune system by participating in the regulation of inflammatory processes.

However, the most well-known use of plasmakinin is with its substitutes, such as Factor VIII. Factor VIII is a protein that plays a key role in the blood clotting process. A lack of factor VIII causes blood clotting problems and can cause bleeding, and also increases the risk of developing hemophilia.

This is why plasmakinin and its substitutes, such as Factor VIII, are used in the treatment of hemophilia and other bleeding disorders. These drugs can be isolated from donor plasma or obtained using recombinant DNA technology.

Although plasmakinin is an important protein for normal blood clotting, its excess may be associated with the risk of thrombosis and other cardiovascular diseases. Therefore, the use of plasmakinin and Factor VIII substitutes should be strictly controlled and prescribed only by a doctor.